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Edited by Robert BaroukiAbstract The present study investigates the regulation of small
ubiquitin-related modiﬁer-1 (SUMO-1) expression in response to
hypoxia in adult mouse brain and heart. We observed a
signiﬁcant increase in SUMO-1 mRNAs and proteins after
hypoxic stimulation in vivo. Because SUMO-1 interacts with
various transcription factors, including hypoxia-inducible factor-
1b (HIF-1b) in vitro, we not only demonstrated that the HIF-1a
expression is increased by hypoxia in brain and heart, but also
provided evidence that SUMO-1 co-localizes in vivo with HIF-
1a in response to hypoxia by demonstrating the co-expression of
these two proteins in neurons and cardiomyocytes. The speciﬁc
interaction between SUMO-1 and HIF-1a was additionally
demonstrated with co-immunoprecipitation. These results indi-
cate that the increased levels of SUMO-1 participate in the
modulation of HIF-1a function through sumoylation in brain and
heart.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Small ubiquitin-related modiﬁer-1;
Hypoxia-inducible factor-1a; Hypoxia; Brain; Heart; Mouse1. Introduction
The ubiquitin system has been implicated as a key intracel-
lular signaling pathway for posttranslational modiﬁcation of
proteins [1]. The small ubiquitin-related modiﬁer-1 (SUMO-1)
is a 11.5 kDa ubiquitin-related protein that is 18% identical to
ubiquitin [2–4]. The expression of SUMO-1 was found in both
the nuclear pore complex and within nuclei in a wide range of
tissues and cell types [2,5,6]. Previous studies have demon-
strated that the SUMO-1 gene is highly conserved between
human and mouse [6,7], and its mRNA and protein are ex-
pressed in the brain and heart in humans and mice [7–11]. The
primary function of SUMO-1 has been suggested to prevent
proteasome-mediated degradation of proteins, in opposition to
ubiquitin [1,12]. Recent experiment has shown that SUMO-1,* Corresponding author. Fax: +46-31-7733531.
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doi:10.1016/j.febslet.2004.05.079via sumoylation, stabilizes nuclear proteins [13]. Although
SUMO-1 expression patterns and its localization may provide
some hints as to the functional involvement of sumoylation, no
experimental evidence for the eﬀect of hypoxia on regulation
of SUMO-1 expression in mouse brain and heart in vivo has
been obtained to date.
Hypoxia-inducible factor-1 (HIF-1) is a heterodimer, com-
posed of a and b subunits (also called the aryl hydrocarbon
receptor nuclear translocator (ARNT)) with molecular masses
of 120 and 91–94 kDa, which belongs to the basic helix–loop–
helix (bHLH)/Per-Arnt-Sim (PAS) family [14,15] and acts as a
functional transcription factor which contributes to a variety
of developmental and postnatal physiological events, as well as
human diseases [16–18]. The two subunits contain bHLH/PAS
domains which mediate dimerization and DNA binding
[16,19,20]. However, the cellular level of HIF-1a mainly reg-
ulates the activities of HIF-1. Moreover, both subunits display
distinct regulation patterns. The expression of HIF-1b is gen-
erally constitutive [21,22], whereas that of HIF-1a mRNA and
protein levels is upregulated in response to hypoxic stimulation
in vivo [23–25]. It is well documented in the literature that the
mechanism of HIF-1a protein degradation under normoxic
conditions is through ubiquitin–proteasome pathway [26–29],
but HIF-1a is stabilized under hypoxia and its degradation is
prevented by hypoxic stimulation [30]. In addition to the ox-
ygen-dependent degradation of HIF-1a that occurs via the von
Hippel Lindau (VHL)-mediated ubiquitination, oxygen-inde-
pendent degradation is also mediated by the p53–Mdm2
complex [31] and by the chaperone Hsp90 inhibitor geldana-
mycin [32]. Recently, several studies have shown that SUMO-1
interacts with various transcription factors and further mod-
ulates their activities [2–4,6]. For instance, SUMO-1 modiﬁed
HIF-1b and further regulated its transcription activity in vitro
[33]. However, we are not aware of any previous reports in
which the association of SUMO-1 and HIF-1a has been shown
either in vivo or in vitro. We propose that another posttrans-
lational modiﬁcation other than ubiquitinylation may serve
as a regulatory mediator to protect HIF-1a protein against
degradation.
In this study, we examined whether SUMO-1 expres-
sion is altered after hypoxic stimulation in adult mouse brain
and heart in parallel to increased levels of HIF-1a protein.ation of European Biochemical Societies.
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HIF-1a in vivo.2. Materials and methods
2.1. Antibodies and reagents
Rabbit polyclonal anti-SUMO-1, mouse monoclonal anti-myosin
heavy chain (MHC), rabbit polyclonal anti-VEGF, goat polyclonal
anti-lamin B, and normal mouse IgG were purchased from Santa Cruz
Biotechnologies, Inc. (Santa Cruz, CA); mouse monoclonal anti-HIF-
1a was purchased from Novus Biologicals, Inc. (Littleton, CO); mouse
monoclonal anti-neuronal nuclear protein (NeuN) was purchased from
Chemicon International, Inc. (Temecula, CA); alkaline phosphatase
conjugated goat-anti-rabbit immunoglobulin were purchased from
Tropix (Bedford, MA); mouse monoclonal anti-b-actin, alkaline
phosphatase conjugated goat-anti-mouse immunoglobulin, and alka-
line phosphatase conjugated mouse-anti-goat immunoglobulin were
purchased from Sigma (St. Louis, MO); normal rabbit serum and
normal goat serum were obtained from DAKO Corp. (Carpinteria,
CA); biotin-SP-conjugated donkey anti-rabbit IgG, ﬂuorescein
(FITC)-conjugated streptavidin and Cy 3-conjugated donkey anti-
mouse IgG were purchased from Jackson ImmunoResearch Labora-
tories, Inc. (West Grove, PA). Other reagents not mentioned in the text
were purchased from Sigma or Merck AG (Darmstadt, Germany) and
were of the highest purity grade available.
2.2. Animal and tissue collections
Eight to 10-week-old male and female mice (C57BL/6) were pro-
vided by Taconic M&B, Denmark. Mice were randomized and housed
in a temperature-controlled animal room (21 2 C) under a constant
12:12-h light:dark cycle. They were fed with standard laboratory food
and water ad libitum for at least one week before the experiments. For
studies involving hypoxic conditions, mice were subjected to systemic
hypoxia in a closed Persplex chamber supplied with a gas mixture
consisting of 10% O2 and 90% N2 using an oxygen (atmospheric and
dissolved) sensor (Model 600, Engineered Systems & Designs Inc.,
USA) for monitoring the O2% concentration, which gradually de-
creases from an ambient 20.9% to 10% during an adaptation time of 30
min. Mice were kept in room air to serve as control. The animals were
killed at day 4 after hypoxic exposure. To prevent protein degradation,
tissues (brain, heart, liver and lung) were either immediately frozen in
liquid nitrogen and stored at )135 C until assayed, or ﬁxed in 4%
formaldehyde neutral buﬀered solution for 24 h at 4 C and embedded
in paraﬃn. In addition, hearts isolated from mice were quickly rinsed
twice in ice-cold HEPES buﬀer (10 mM HEPES, pH 6.95, 115 mM
NaCl, 5 mM KCl, 35 mM sucrose, 10 mM glucose and 4 mM taurine)
at 4 C to remove residual blood before processing. All animal studies
described in this study were reviewed and approved by the ethics
committee at G€oteborg University, Sweden.
2.3. Preparation of whole cell, cytosolic and nuclear protein extracts
The preparation of whole cell protein lysates was performed as
described recently [34]. Brieﬂy, tissues were extracted with ice-cold lysis
buﬀer (50 mM Tris–HCl, pH 7.4, 0.5 M NaCl, 0.5% Nonidet-P40, 50
mM NaF, 0.5 mM Na3VO4 and 20 mM Na4P2O7  10H2O, 2 mM
EDTA, 1 mM phenylmethylsulfonylﬂuoride (PMSF), 10 lg/ml apro-
tinin, 10 lg/ml leupeptin, 10 lg/ml pepstatin and 1 mM DTT). Cyto-
solic and nuclear extracts were performed by following a minor
modiﬁed procedure based on previously described protocol [35]. Tis-
sues were gently homogenized using a pellet pestle mixer (Merck
KGaA, Darmstadt, Germany) in ice-cold TEDG buﬀer (25 mM Tris,
pH 7.4, 1 mM EDTA, 1 mMDTT and 10% glycerol) in the presence of
protease inhibitors (10 lg/ml aprotinin, 10 lg/ml leupeptin, 10 lg/ml
pepstatin and 1 mM PMSF). After centrifugation at 800 g, the su-
pernatant was removed and centrifuged with glycerol at 100 000 g for
1 h at 4 C to obtain cytosolic extracts. The nuclear pellets (presence
and purity of the nuclei were checked under a microscope) were re-
suspended with ice-cold STMG buﬀer (20 mM Tris, pH 7.8, 250 mM
sucrose, 1.1 mM MgCl2, 8.5% glycerol and 5% Triton X-100). After
centrifugation at 1500 g for 10 min at 4 C, the pellets were washed
one time with ice-cold STMG buﬀer without 5% Triton X-100 and
then centrifuged at 1500 g for 10 min at 4 C. The pellets were ho-
mogenized in ice-cold lysis buﬀer (20 mM HEPES, pH 7.9, 420 mMNaCl, 1 mM EDTA, 0.1 mM EGTA and 25% glycerol) in the presence
of protease inhibitors and incubated for 30 min at 4 C. The nuclei
were pelleted by centrifugation at 13 000 g for 30 min at 4 C. The
supernatants were collected as nuclear extracts. Protein concentrations
were determined by BCA protein assay (Pierce, Rockford, IL) with
bovine serum albumin (BSA) as standard.2.4. Immunoblotting and co-immunoprecipitation
The immunoblotting and co-immunoprecipitation experiments was
performed according to a procedure previously described [11]. Brieﬂy,
equal amounts of cellular extract were separated by 10% SDS–poly-
acrylamide gels (Novex) and transferred to polyvinyldiﬂuoride mem-
branes (Amersham International, Buckinghamshire, UK). The speciﬁc
antibodies against SUMO-1 or HIF-1a diluted to 1:1000 or 1:500,
respectively, were used to probe the blots. Binding was detected with
alkaline phosphatase-linked secondary antibody (polyclonal secondary
antibody at a dilution of 1:40 000 or monoclonal secondary antibody
at a dilution of 1:80 000, respectively). Blots were reprobed with a
monoclonal anti-b-actin antibody for loading normalization without
stripping membranes.
For co-immunoprecipitation experiments, tissues were extracted
with ice-cold lysis buﬀer (25 mM Tris–HCl, pH 8.0, 150 mM NaCl,
0.5% Nonidet P-40, 1% SDS, 200 lM sodium deoxycholate, 1 mM
DTT, 5 mM EDTA, 0.5 mM PMSF, 10 mM N-ethylmaleimide
(NEM), 10 mM iodoacetamide, and a cocktail of protease inhibitors
(Roche Diagnostics GmbH, Mannheim, Germany)). Either anti-SU-
MO-1 or anti-HIF-1a antibodies were added to 500 lg protein extracts
and incubated for 4 h at room temperature. Immune complexes were
obtained by the addition of 50 ll Pansorbin cells (Calbiochem, San
Diego, CA). The resulting immobilized immune complexes were wa-
shed in RIRA buﬀer (50 mM Tris–HCl, pH 7.8, 150 mMNaCl, 15 mM
MgCl2, 0.5% Nonidet P-40, 0.3% Triton X-100, 0.5% sodium deoxy-
cholate, 5 mM EDTA, 1 mM DTT and a cocktail of protease inhibi-
tors), which was supplemented with 10 mM NEM and 10 mM
iodoacetamide. The bound protein was eluted by boiling in 30 ll SDS
sample reducing loading buﬀer (Novex) for 5 min. Immunoprecipi-
tated complexes for either SUMO-1 or HIF-1a were loaded in the
same gels which were run at the same time within the same electro-
phoresis unit and examined by immunoblotting as described above.
To reprobe the blot with another antibody, the blot was rehydrated
in methanol, rinsed and incubated with stripping buﬀer (62.5 mM
Tris–HCl, 2% SDS and 100 mM b-mercaptoethanol, pH 6.8) at 50 C
for 30 min.
2.5. Histology and immunohistochemistry
Serial 5 lm sections were cut from the paraﬃn-embedded blocks and
allowed to dry overnight at 37 C, and stained with hematoxylin and
eosin (H&E) using standard protocols. Immunohistochemical analysis
was performed as described previously [11,34]. In brief, after depa-
raﬃnization and rehydration, adjacent paraﬃn-embedded sections
were pretreated with 0.01 M sodium citrate buﬀer (pH 6.0), 3% hy-
drogen peroxide in Tris-buﬀered saline (TBS, 50 mM Tris and 0.9%
NaCl, pH 7.5), and blocked with 3% BSA and 5% normal goat serum
in TBS with 0.3% Triton X-100. Sections were incubated with the
primary antibody against SUMO-1 diluted to 1:500 in TBS containing
3% BSA overnight at 4 C. Bound antibodies were detected using the
avidin-biotinylated-peroxidase complex detection system (ABC Kit,
Vector Laboratories, Inc., Burlingame, CA) according to the manu-
facturer’s instructions. Immunostaining was then visualized using 3,3-
diaminobenzidine tetrahydrochloride for 5–10 min. Sections were
washed and mounted with Histo Mounting Medium (Mountex, His-
tolab, Sweden). Slides were viewed on a Nikon E-1000 microscope
(Japan) and photomicrographed.
For double-ﬂuorescence immunohistochemistry of SUMO-1 and
HIF-1a, sections were incubated with a mixture of antibodies against
SUMO-1 and HIF-1a diluted to 1:500 and 1:200, respectively, in PBS
containing 1% BSA and 3% fat-free milk. Each primary antibody was
serially diluted to optimize the concentration used to achieve maxi-
mum sensitivity and speciﬁcity. Immunodetection was accomplished
using the species-speciﬁc secondary antibodies, either a biotin-conju-
gated anti-rabbit antibody together with streptavidin conjugated with
FITC or Cy 3-conjugated anti-mouse antibody. Sections were washed
and mounted with Fluorescent Mounting Media (DAKO, Carpinteria,
CA). Slides were viewed on a ZEISS Axioskop II microscope (Ger-
many) and photomicrographed. The immunohistochemical ﬁndings
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from multiple animals. The resulting stain was evaluated by two
blinded observers.
To assess speciﬁcity of SUMO-1 and HIF-1a antibodies, separate
control sections were processed with non-immune rabbit and mouse
IgG in place of the primary antibodies. Additional control sections
were processed as above, but with the omission of either primary or
secondary antibody. These control sections showed no labeling.
2.6. RNA preparation, RT-PCR and Northern hybridization analyses
Total RNA was isolated from individual tissues using Trizol Re-
agent (Life Technologies, Inc.) according to the manufacture’s in-
structions. The integrity of extracted RNA was determined by
visualizing ethidium bromide-stained 28S and 18S rRNA bands after
migration on 1.2% denatured agarose gel and concentration was de-
termined by spectrophotometry. Any contaminating genomic DNA
was digested by RNase-free DNase.
For ampliﬁcation of the targets, RT and PCR were run in two sep-
arate steps. Brieﬂy, equal amounts of total RNA (2 lg/each) were heat
denatured and reverse transcribed by incubation at 42 C for 60 min
and at 52 C for another 60 min with 12.5 UAMV-RT (Promega Corp.,
Madison, WI), 20 U ribonuclease inhibitor (RNasin) (Promega), 200
nM deoxy-NTP mixtures and 1 nM random hexamers (Promega) in a
ﬁnal volume of 30 ll of 1 AMV-RT buﬀer. The reaction was termi-
nated at 97 C for 5 min and then chilled on ice, followed by dilution of
RT cDNA samples with nuclease-free H2O (ﬁnal volume 100 ll). For
PCR analysis, 10 ll aliquots of the cDNA samples were ampliﬁed in 50
ll of 1 PCR buﬀer in the presence of 2.5 U Taq-DNA polymerase
(Promega), 200 nM deoxy-NTP mixtures and 1 nM of each primer for
SUMO-1 gene (50-GAGAAGGGACGGATTTGTAAACCTCA-30
(forward) and 50-TGACCCCCCGTTTGTTCCTGA-30 (reverse))
(Sigma-Genosys Ltd, Cambridgeshire, UK). PCRs consisted of a de-
naturing step at 97 C for 3 min, the cycles of ampliﬁcation deﬁned by
denaturation at 96 C for 0.5 min, annealing at 57 C for 1 min and
extension at 72 C for 2 min. A ﬁnal extension cycle of 72 C for 10 min
was included. The amount of cDNA and the number of cycles were
optimized to ensure ampliﬁcation in the exponential phase of PCR.
Diﬀerent numbers of cycles were tested for SUMO-1 (ranging between
25 and 40). Based on the analysis of cycle dependency of the intensity of
the generated PCR signals, 30 cycles were chosen for further analysis of
SUMO-1. PCR products were electrophoresed in 1.5% agarose gels
along with a 100 bp DNA ladder (Fermentas, Hanover, MD) and vi-
sualized by ethidium bromide staining. The predicted size of the PCR-
ampliﬁed products was 389 bp for SUMO-1. The intensity of bands was
digitally photographed. The speciﬁcity of ampliﬁed products was con-
ﬁrmed by including the control reactions containing water alone or
RNA in the absence of RT. No PCR products were obtained in these
experiments for any of the pairs of primers.
Northern hybridization analyses were performed as previously de-
scribed [36]. RNA samples (12 lg/each) were resolved onto 1.2% de-
naturing agarose gels and transferred onto Hybond-XL nylon
membranes (Amersham International, Aylesbury, UK) using the
capillary method. The membranes were cross-linked by short-wave UV
irradiation and prehybridized at 65 C for at least 4 h in a solution
containing 50% deionized formamide, 3 SSC, 5 Denhardt’s solu-
tion, 0.1 g/l heat-denatured calf-thymus DNA, 1% SDS, and 0.1 g/l
yeast transfer RNA. For generation of cRNA probe, DNA fragment
generated by RT-PCR corresponding to 225–938 of SUMO-1 cDNA
[7] was subcloned into T-vector (Promega) and used as template. [32P]-
labeled complementary RNA (cRNA) probes speciﬁc for the SUMO-1
gene was generated using the Riboprobe System II Kit (Promega,
Medison, WI) before use. Hybridization was carried out at 66 C
(cRNA probe) overnight in the same pre-hybridization solution after
adding the probe. After hybridization, the membranes were washed in
2 SSC, 0.1% SDS for 20 min at room temperature, in 0:5 SSC, 0.1%
SDS twice for 30 min at 65 C, and twice in 0:1 SSC, 0.1% SDS for 1
h at 65 C. The ﬁlters were exposed to Kodak X-ray ﬁlms (Kodak
XAR-5, Eastman Kodak, Rochester, NY) at )70 C for 8–24 h.2.7. Data analysis and statistics
All experiments were repeated three times if not otherwise stated.
Results are expressed as meansS.E.M. The data were analyzed using
Analyse-It program (Analyse-It Software, Ltd., UK). One-way AN-
OVA with post hoc Tukey’s test was used for multiple comparisons. A
P value <0.05 was considered signiﬁcant.3. Results
3.1. Eﬀect of hypoxic stimulation on SUMO-1 gene expression
in vivo
To investigate whether the expression of SUMO-1 could be
aﬀected by hypoxia in adult mice in vivo, we performed im-
munoblotting and immunohistochemical analyses using both
brain and heart tissues. When the nuclear and cytosolic ex-
tracts were subjected to immunoblotting analyses, we observed
that free SUMO-1 protein with a molecular mass of approxi-
mately 18.7 kDa [37] was present in the nuclear fraction, but
not in the cytosolic fraction (data not shown). This is in line
with previous studies demonstrating that SUMO-1 is present
in the cell nucleus [2,5,6]. Immunoblotting analyses revealed
that SUMO-1 protein expression was signiﬁcantly increased in
brain and heart from both female and male mice after hypoxic
stimulation compared to normoxic conditions, which served as
controls (Figs. 1A and 2A). Moreover, immunohistochemical
labeling revealed that the number of SUMO-1-positive cells
was also signiﬁcantly increased in brain and heart after hyp-
oxic stimulation compared to normoxic conditions (Figs. 1B
and 2B), which is in agreement with immunoblotting analyses.
In addition, double-immunoﬂuorescence analysis demon-
strated SUMO-1-positive cells in brain sections from hypoxia
mice corresponded to NeuN protein positive-cells, a marker
for neuron-speciﬁc nuclear protein (data not shown) [38,39]. In
heart tissues, SUMO-1 was expressed in cardiomyocytes
because immunohistochemical analyses demonstrated that
immunolabeling of myosin heavy chain (MHC) speciﬁc for
cardiomyocytes was predominantly associated with SUMO-
1-positive cell cytoplasm within the same cells in heart sections
[40]. Omission of the primary antibody eliminated the signal
(data not shown).
Northern analysis was demonstrated that one major RNA
band hybridized to a mouse SUMO-1 cDNA probe in both
brain and heart. The increase of SUMO-1 protein is paral-
leled by a rapid increase of SUMO-1 mRNA in both brain
(Fig. 3A) and heart (Fig. 3B) after hypoxic stimulation.
Using speciﬁc RT-PCR primer pairs for mouse SUMO-1, we
demonstrated that a single band in both brain and heart
corresponded to the predicted size based on the mouse
SUMO-1 gene sequence. RT-PCR of SUMO-1 mRNA
expression conﬁrmed upregulated by hypoxia (data not
shown).
3.2. Increase of HIF-1a protein expression occurs
predominantly in nuclear fraction
HIF-1a is required to regulate the response to hypoxia in
almost every tissue in humans and rodents [23–25,41–44].
Because HIF-1a has a short half-life in a normoxic environ-
ment [28], we added CoCl2, which inhibits HIF-1a degrada-
tion [45], to tissue lysis buﬀer during protein preparation. To
conﬁrm the analyses of HIF-1a expression, both nuclear and
cytosolic extracts from brain and heart tissues were analyzed
by immunoblotting analyses. We found that HIF-1a protein
was present in the nuclear fraction from hypoxia, but not
from normoxia in brain and heart of both female and male
mice (Fig. 4A). This is well in accordance with the immu-
nohistochemical results obtained by us and others [25]. In
contrast, we did not observe HIF-1a protein expression in
either the nuclear or the cytosolic fractions under normoxic
condition nor the cytosolic fraction under hypoxic condition
Fig. 2. Eﬀect of hypoxic stimulation on expression of SUMO-1 protein
in mouse heart. (A) Protein samples were isolated from heart of female
and male mice treated with either normoxia or hypoxia. Total protein
(30 lg per lane) was subjected to immunoblotting analysis of SUMO-1
expression. The representative blots show data from ﬁve animals in
each group. The level of b-actin was used as an internal standard to
verify equal loading of proteins. The migrations of SUMO-1 and b-
actin proteins are designated by arrowheads. The SUMO-1/b-actin
ratio was calculated for each sample and the values were the relative
SUMO-1 expression (the average value for the normoxia female ani-
mals was set to 1). Results are presented as meansS.E.M. from ﬁve
mice/group. **, P < 0:01. NA, normoxia; HA, hypoxia. (B) Cellular
localization of SUMO-1 protein expression in female mouse heart.
H&E stains demonstrating the cardiomyocytes of mouse heart (left
panel). Immunoreactivity of SUMO-1 in the heart sections showing
increased immunolabeling intensity in hypoxia (right panel) compared
with normoxia (middle panel). Random sections from three female
and male mice provided similar results. All micrographs are at 40
magniﬁcations.
Fig. 1. Eﬀect of hypoxic stimulation on expression of SUMO-1 protein
in mouse brain. (A) Protein samples were isolated from brain of fe-
male and male mice treated with either normoxia or hypoxia. Total
protein (30 lg per lane) was subjected to immunoblotting analysis of
SUMO-1 expression. The representative blots show data from ﬁve
animals in each group. The level of b-actin was used as an internal
standard to verify equal loading of proteins. The migrations of SU-
MO-1 and b-actin proteins are designated by arrowheads. The SU-
MO-1/b-actin ratio was calculated for each sample and the values
were the relative SUMO-1 expression (the average value for the nor-
moxia female animals was set to 1). Results are presented as mean-
sS.E.M. from ﬁve mice/group. **, P < 0:01. NA, normoxia; HA,
hypoxia. (B) Cellular localization of SUMO-1 protein expression in
female mouse brain. H&E stains demonstrating the neurons of mouse
brain (left panel). Immunoreactivity of SUMO-1 in the brain sections
showing increased immunolabeling intensity in hypoxia (right panel)
compared with normoxia (middle panel). Random sections from three
female and male mice provided similar results. All micrographs are at
40 magniﬁcations.
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B, a representative protein speciﬁcally located in the cell
nucleus, was examined in order to conﬁrm the proper ex-
traction of cytoplasmic and nuclear fractions in both brain
and heart (Fig. 4A), and conﬁrmed that the cytosolic extracts
of both brain and heart tissue samples were not contaminated
with nuclear fractions. Liver and lung tissue from hypoxic
mice served as positive and negative controls (data not
shown) [25].3.3. Nuclear co-localization of SUMO-1 and HIF-1a under
hypoxic conditions
Because the expression of SUMO-1 and HIF-1a signiﬁcantly
increased in a similar pattern in brain and heart under hypoxic
conditions, it was of interest to determine if these two mole-
cules were also co-expressed. We carried out double-labeled
immunoﬂuorescence experiments on the same brain and heart
tissue sections from mice after hypoxic stimulation using an-
tibodies that recognize each of these proteins. Simultaneous
labeling with SUMO-1 and HIF-1a antibodies showed that
Fig. 3. Eﬀect of hypoxic stimulation on expression of SUMO-1 mRNA in mouse brain (A) and heart (B). mRNA samples were isolated from brain
(A) and heart (B) of female and male mice treated with either normoxia or hypoxia. Total mRNA (12 lg per lane) was subjected to Northern
hybridization analysis of SUMO-1 expression. The calculated size (kilobase pairs) of the speciﬁc transcript is indicated on the right. The repre-
sentative blots show data from three animals in each group. The level of 18S and 28S was used as an internal standard to verify equal loading of
mRNA. The intensity of the bands was quantitated by densitometry. The SUMO-1/18S ratio was calculated for each sample and the values were the
relative SUMO-1 expression (the average value for the normoxia female animals was set to 1). Results are presented as means S.E.M. from three
mice/group. **, P < 0:01. NA, normoxia; HA, hypoxia.
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localized in the nucleus. The merged image clearly revealed
that both SUMO-1 and HIF-1a co-expressed in the neurons
(Fig. 4B) and cardiomyocytes (Fig. 4C) under hypoxic condi-
tions. No immunoﬂuorescence staining was evident in control
sections reacted in the absence of either anti-SUMO-1 or anti-
HIF-1a antibodies (data not shown).
3.4. SUMO-1 interacts directly with HIF-1a in response to
hypoxic stimulation
In order to determine if SUMO-1 and HIF-1a interact in the
intracellular environment in vivo, we performed co-immuno-
precipitation experiments. Because sumoylation is fully
reversible protein modiﬁcation [2–4], demonstration of SU-
MO-1 functions as a mediator of protein–protein interactions
through isopeptide linked to target proteins could be techni-
cally challenging. Therefore, we used iodoacetamide as an
isopeptidase inhibitor and NEM, to block speciﬁc SUMO-1
proteases in vivo [46], and to prevent SUMO-1 de-conjugation
to proteins when cell lysates were prepared [47]. Total tissue
lysates were subjected to immunoprecipitation with anti-HIF-1a or anti-SUMO-1 antibodies in order to obtain endogenous
either SUMO-1 or HIF-1a from normoxic and hypoxic brains
and hearts. Subsequently, the immunocomplexes were ana-
lyzed by immunoblotting analyses with an anti-HIF-1a anti-
body to detect the interacted complexes of SUMO-1/HIF-1a.
We observed that: (1) in the anti-HIF-1a immunoprecipitates,
a major single HIF-1a-immunoreactive band was revealed in
brain and heart tissues from mice after hypoxic stimulation
(Fig. 5, left panel), consistent with the observation in direct
immunoblotting analyses (Fig. 4A), (2) in the anti-SUMO-1
immunoprecipitates, three HIF-1a-immunoreactive bands
with apparent molecular masses of 198, 152 and 105 kDa
were detected in hypoxic brain and heart. In contrast, a protein
of the expected HIF-1a (120 kDa) was not recognized in the
anti-SUMO-1 immunoprecipitates (Fig. 5, middle panel) and
(3) two slowly migrating immunoreactive bands (198 and
152 kDa) compared to predicted molecular weight of HIF-1a
(120 kDa) under reducing gel-running conditions, were also
detected after stripped and reprobed same membranes with
the anti-SUMO-1 antibody (Fig. 5, right panel), suggesting
that these two high molecular bands are speciﬁc for HIF-1a
Fig. 4. Eﬀect of hypoxic stimulation on expression of HIF-1a protein
in mouse brain and heart (A). Nuclear and cytosol extracts were iso-
lated from brain or heart of female and male mice treated with either
normoxia or hypoxia. Total protein (30 lg per lane) was subjected to
immunoblotting analysis of SUMO-1 expression. The expression of
lamin B was examined in order to conﬁrm the proper extraction of
nuclear and cytoplasmic fractions. The representative blots show data
from ﬁve animals in each group. The molecular mass markers (kDa,
kilodaltons) are indicated on the left. Fe: female mouse, M: male
mouse. Representative micrographs of brain (B) and heart (C) tissue
sections from mice treated with hypoxia were subjected to double-
immunoﬂuorescence staining. The green signal was obtained with
FITC-conjugated streptavidin and the red signal with an anti-mouse
Cy 3 antibody. Superimposing the two colors (merged images) results
in a yellow signal, when both proteins co-localize. Nuclear co-locali-
zation of SUMO-1 and HIF-1a is seen in neurons and cardiomyocytes
under hypoxic condition. Each set of images is representative of
staining patterns seen in specimens from three female and male mice
examined in the respective groups. All micrographs are at 63 mag-
niﬁcations in B and at 10 magniﬁcations in C.
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tected with anti-SUMO-1 antibody in the same membrane.
This could be due to reduced sensitivity after stripping oﬀ anti-
HIF-1a antibody. To determine whether we could detect those
HIF-1a-reactive bands again, we performed immunoblotting
on the same blot using anti-HIF-1a antibody. This time, we
also detected three HIF-1a-reactive bands that had same mo-
bility to those detected in the previous experiment (data not
shown). Thus, this experiment provides strong evidence that
slower migrating bands are immunoreactive for SUMO-1/
HIF-1a conjugates.4. Discussion
In the present study, we have demonstrated that SUMO-1
gene expression is enhanced by hypoxic stimulation in adult
mouse brain and heart in vivo. Furthermore, SUMO-1 not
only co-localizes with HIF-1a under hypoxic conditions in
neurons and cardiomyocytes, but also physically interacts with
HIF-1a in response to hypoxic stimulation in vivo, suggesting
sumoylation of HIF-1amay be of importance to stabilize HIF-
1a protein and its action.
Recently, it has been reported that both SUMO-1 mRNA
and protein levels are increased after hypoxic stimulation in
the number of cultured cell lines [48], which is in line with the
present in vivo data. The signiﬁcant increases in SUMO-1
mRNAs and proteins after hypoxic stimulation in brain and
heart from both adult female and male mice suggested, to us, a
role for SUMO-1 in the hypoxic response of those tissues.
Previous studies have been demonstrated that SUMO-1 con-
jugates to a number of functional diverse proteins involved in a
multi-enzyme ligase process, so-called sumoylation, a post-
translational processes for protein modiﬁcation [2,3,5,6]. Ini-
tiation of SUMO-1 activation requires the conversion of its
precursor to a mature form by speciﬁc proteases [3]. These
SUMO proteases needed for maturation of SUMO-1 have
been identiﬁed in the bovine and human brain [46,49]. Sub-
sequently, mature SUMO-1 can be covalently conjugated to
target proteins by speciﬁc enzymatic cascades and that further
regulates cellular functions [2,3,5,6]. On the other hand,
SUMO proteases play a dual role because they can also cleave
the isopeptide bond between SUMO-1 and the target proteins
to release SUMO-1 in unmodiﬁed forms [3,47]. Indeed, no
immunoreactive bands for SUMO-1/HIF-1a conjugates were
detectable in the absence of the NEM and iodoacetamide in
lysis buﬀer for brain and heart protein preparations (data not
shown), suggesting that SUMO-1 conjugates to target proteins
is a reverting process.
HIF-1, a heterodimer composed of HIF-1a and HIF-1b
[14,15] that is an ubiquitously expressed transcriptional master
regulator of several genes involved in mammalian oxygen
homeostasis in many tissues. The formation of HIF-1a with
HIF-1b complex via their bHLH/PAS domains [20] is required
for its transcriptional activity. However, the expression and
activity of HIF-1a subunit are oxygen-regulated [23–25]. Pre-
vious studies have been shown that the expression of HIF-1a is
normally low and upregulated after hypoxic conditions in the
brain and heart of the rodents [25,41,42]. Similarly, there are
no detectable levels of HIF-1a protein in normal human brain
and heart tissues, except for its protein overexpression asso-
ciated with human tumorigenesis, including brain tumors
[43,44]. Using in vivo hypoxia-induced model, we conﬁrmed
that speciﬁc expression of HIF-1a protein in mouse brain and
heart after hypoxic stimulation is signiﬁcantly increased, which
is in line with previous studies [25,41,42]. Gene targeting
studies in mice have shown that HIF-1a null mice exhibits
abnormal neural development and impaired cardiovascular
responses to chronic hypoxia [50,51], indicating that HIF-1a
plays a critical role in brain and heart. Furthermore, several
studies have demonstrated that in normoxic cells HIF-1a is
targeted for rapid ubiquitinlation by the proteasomal degra-
dation, and that accumulation in hypoxia involves a reduction
in this degradation, mostly due to stabilization of HIF-1a
protein [26–29]. In contrast, SUMO-1 modiﬁcation has been
Fig. 5. SUMO-1 interacts directly with HIF-1a in response to hypoxia in vivo. Whole tissue extracts isolated from brain or heart of mice treated with
either normoxia or hypoxia, were immunoprecipitated with either anti-HIF-1a or anti-SUMO-1 antibodies. Subsequently, each immunoprecipitate
was immunoblotted with anti-HIF-1a (left and middle panels). The immunoreactive bands corresponding to unconjugated HIF-1a (arrow) and
SUMO-1-conjugated HIF-1a (a square bracket) and the molecular weight markers (kDa, kilodaltons) are indicated. Unidentical band was marked
by an asterisk. After enhanced chemiluminescence development, the blot used in left and middle panels was stripped and reprobed with the anti-
SUMO-1 antibody (right panel). The blot shown is a representative one of two independent experiments with a diﬀerent tissue sample in each lane
without sex diﬀerence. IP: immunoprecipitation, IB: immunoblotting, Br: brain, He: heart.
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the stability of nuclear protein [13]. Therefore, a proposed
function for hypoxia-induced SUMO-1 expression is to con-
jugate and stabilize HIF-1a protein under hypoxia in brain
and heart. Interestingly, HIF-1a and HIF-1b has same di-
merization and DNA binding domains, including bHLH and
PAS. In particular, the sumoylation site of HIF-1b is localized
within PAS motif [33]. One of the novel ﬁndings of the present
study is the demonstration of the interaction of SUMO-1 with
HIF-1a in response to hypoxia in adult mouse brain and heart
in vivo. Our results clearly demonstrated that SUMO-1 not
only co-localizes with HIF-1a in the neurons and cardiomyo-
cytes, but also conjugates to HIF-1a in response to hypoxic
stimulation. Although immunoprecipitation assays may not
allow quantitative analysis of the distribution of various
SUMO-1/HIF-1a conjugates that are immunoprecipitated,
these data support the hypothesis that SUMO-1 may modify
HIF-1a through sumoylation in response to hypoxia. Based
upon the observations that: (1) when SUMO-1 is expressed,
the interaction of SUMO-1 with HIF-1a is absent in the brain
and heart under normoxic condition and (2) no SUMO-1
proteins are detected in the cytosolic fractions of brain and
heart under normoxic or hypoxic conditions. Although an in
vitro study demonstrated that HIF-1a may be translocated
from the cytoplasm to the nucleus in response to hypoxic
stimulation [27], it appears that HIF-1a undergoing hypoxia-
induced SUMO-1 modiﬁcation takes place in the cell nucleus
of both brain and heart [33,37]. If true, further investigation
into the details of sumoylation of HIF-1a during hypoxia re-
sponses will be required. HIF-1a is critical in regulating a
variety of hypoxia-inducible genes in several systems. SUMO
modiﬁcation of proteins has recently been shown to act as a
stabilizing factor by counteracting ubiquitin-mediated degra-
dation [13]. Therefore, an increase in SUMO-1 may contribute
to HIF-1a stabilization during hypoxic conditions, which is of
importance for HIF-1a-dependent gene activation (i.e., the
activation of vascular endothelial growth factor (VEGF),
erythropoietin, glucose transporters and endothelial cell pro-
liferation) involved in vascular biology, cellular metabolism
and tissue tolerance to hypoxia [17]. VEGF has been shown in
vivo and in vitro to be the principal mediator of hypoxia-induced angiogenesis [17,18,31,52]. In support of previous
ﬁndings, we demonstrated that, using immunoblotting exper-
iments with the same brain and heart tissues, which had been
used for the detection of SUMO-1 and HIF-1a expression,
indeed, the induction of HIF-1a protein is accompanied with
increased production of VEGF protein by hypoxia in both
brain and heart, albeit to various degrees in vivo (data not
shown). Such downstream targets of HIF-1a may be of con-
siderable clinical importance in obstructive ischemic diseases
of the brain, heart and lower extremities. Thus, modulation of
HIF-1a level and its activity through manipulation of SUMO-
1 expression could be one of the attractive approaches for the
eﬀective treatment of ischemic disease.
In summary, this is the ﬁrst report investigating the eﬀect of
hypoxia on SUMO-1 gene expression in adult mouse brain and
heart in vivo. The hypoxia-induced increase in SUMO-1 ex-
pression is correlated with the induction of HIF-1a protein as
a transcription regulatory mediator in response to hypoxia.
Moreover, we have shown that SUMO-1 not only co-localizes
but also interacts with HIF-1a. Our results provide support to
the notions that the regulation of endogenous SUMO-1 may
modify HIF-1a and further regulate HIF-1a function by su-
moylation pathway, which remain to be identiﬁed.
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